Clinical Trial Detail

NCT ID NCT02388906
Title Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Nivolumab

Ipilimumab

Age Groups: adult

No variant requirements are available.